Overview

SK bioscience has published ESG reports since 2022 to transparently share our ESG strategies and performances with our stakeholders. We will disclose our ESG management outcomes by publishing annual ESG report and incorporate the opinions of stakeholders into our management activities.

Reporting Guidelines

This report has been prepared in accordance with the Global Reporting Initiative(GRI) Standards 2021 and reflects the Sustainability Accounting Standards Board(SASB) Standards to incorporate industry-specific major issues. In addition, Task Force on Climate-related Financial Disclosure(TCFD) has been adopted in this report.

Reporting Period & Scope

This report covers performance and activities from January 1 to December 31, 2023. It includes partial data for the first half of 2024. For some indicators, data for the past three years are presented to show the latest trend of quantitative performance. The scope of this report encompasses the entire ESG performance of the domestic business sites of SK bioscience. Financial information is prepared based on consolidated financial statements under K-IFRS(Korean International Financial Standards). Non-financial information is also prepared in accordance with the fiscal year.

Reporting Assurance

SK bioscience conducted an independent assurance process from the British Standards Institution(BSI), a professional assurance agency, to secure the data reliability and improve the quality of the report. And the assurance followed the AA1000 Assurance Standard(AA1000AS) serving as a global standard for assurance on sustainability information.

Report Contact

• Department : SK bioscience ESG Team
• Address : 310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
• E-mail : esg.bs@sk.com